Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | SVP - GENERAL COUNSEL | December 07, 2022 | December 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date December 07, 2022 · Filed December 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,092 |
Ending reported balance
After 2022-12-08 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2022-12-07 · Exercise / conversion · Acquired 800 · Balance 26,892 Row 2 · 2022-12-07 · Sale · Disposed 800 · Balance 26,092 Row 3 · 2022-12-08 · Exercise / conversion · Acquired 7,450 · Balance 33,542 Row 4 · 2022-12-08 · Sale · Disposed 7,450 · Balance 26,092 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2024-08-09 | Direct | 37,212 |
Reported balance
After 2022-12-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-12-07 · Exercise / conversion · Disposed 800 · Balance 37,212 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2024-08-09 | Direct | 29,762 |
Reported balance
After 2022-12-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-12-08 · Exercise / conversion · Disposed 7,450 · Balance 29,762 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.33 · Expires 2025-08-08 | Direct | 66,248 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 66,248 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 39,872 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 39,872 F2: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.60 · Expires 2026-08-07 | Direct | 53,160 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 53,160 F3: Options to purchase13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 29,968 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 29,968 F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 39,960 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 39,960 F6: Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-12-07 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance Not disclosed F7: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 33,300 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 33,300 F8: Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $93.11 · Expires 2028-03-01 | Direct | 43,988 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 43,988 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 18,240 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 18,240 F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 24,320 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 24,320 F10: Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 24,664 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · Balance 24,664 F11: Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #1 | 5,320 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 5,320 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust #2 | 5,320 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,320 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,716 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 6,716 F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,668 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 4,668 F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,936 |
Reported balance
Holding disclosure · report date 2022-12-07 · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · Balance 7,936 F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12: 2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Fully exercisable.
F3: Options to purchase13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023.
F4: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F5: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F6: Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024.
F7: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F8: Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F9: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
F11: Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026.
F12: 2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2020 Filed Dec 2, 2020 23:01 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 10,857 | $106.59 | $1,157,247.63 |
DisclosureSEC source: 0001562180-20-007023 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000292 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,724 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: On 8/9/2020, the Board of Directors certified vesting of 1,724 performance RSUs. F4 · derivative.expiration_date: On 8/9/2020, the Board of Directors certified vesting of 1,724 performance RSUs. Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 849 | $265.76 | $225,630.24 |
DisclosureSEC source: 0000914190-20-000292 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,186 Read SEC document |
| August 09, 2020 Filed Aug 11, 2020 22:22 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,724 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000292 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 18 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F13 · derivative.exercise_date: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 8,325 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 17 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires 2027-08-05 F12 · derivative.exercise_date: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 9,990 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 16 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,990 Underlying: Common Stock · 9,990 shares Expires 2027-08-05 F11 · derivative.exercise_date: Options to purchase 2,498 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 2,497 shares vest on each of 8/5/2023 and 8/5/2024. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 7,492 | $0.00 Strike: $267.87 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 15 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,492 Underlying: Common Stock · 7,492 shares Expires 2027-08-05 F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 22:40 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,679 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-20-000247 · edgar.xml · derivative · entry 14 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,679 Underlying: Common Stock · 1,679 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,079 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · derivative · entry 10 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 921 Underlying: Common Stock · 9,079 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Vests 2,500 share(s) on 07-Aug-2016, 2,500 share(s) on 07-Aug-2017, 2,500 share(s) on 07-Aug-2018, 1,579 share(s) on 07-Aug-2019 Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 74 | $278.84 | $20,634.16 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 9 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,746 | $278.06 | $763,555.51 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,385 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.7700 to $278.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,954 | $277.28 | $541,812.15 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,131 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.6500 to $277.6200, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 400 | $276.03 | $110,410.00 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,085 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.4000 to $276.3500, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 918 | $274.80 | $252,270.81 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,485 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.3100 to $275.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,042 | $273.33 | $558,143.33 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,403 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.8500 to $273.7900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 505 | $272.48 | $137,601.29 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,445 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.8500 to $272.8300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 440 | $270.97 | $119,225.00 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,950 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.6400 to $271.5000, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2020 Filed Jul 13, 2020 20:02 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 9,079 | $108.49 | $984,980.71 |
DisclosureSEC source: 0001562180-20-005109 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 5,995 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,995 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,600 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,600 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,800 | $260.38 | $989,453.50 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0800 to $261.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 2,195 | $259.72 | $570,079.25 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,111 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $259.0500 to $260.0400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,600 | $94.35 | $150,960.00 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 21:58 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,995 | $108.49 | $650,397.55 |
DisclosureSEC source: 0000914190-20-000196 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 21:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 8,000 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 21:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 200 | $216.75 | $43,350.00 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · nonDerivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,711 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.71 to $216.79 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 21:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 4,147 | $216.01 | $895,783.93 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · nonDerivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,911 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.69 to $216.53 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 21:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,227 | $215.17 | $694,337.78 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · nonDerivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,058 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.69 to $215.68 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 21:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 426 | $214.32 | $91,300.15 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,285 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.67 to $214.66 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 21:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 8,000 | $94.35 | $754,800.00 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Dec 17, 2019 21:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GiftCommon Stock | 492 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000488 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,711 F1 · shares: Represents a transfer of shares to a charitable donor advised fund. The reporting person retained no pecuniary interest in the transferred shares. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 1,759 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000328 · edgar.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/19/2019, the Board of Directors certified vesting of 1,759 performance RSUs. F3 · derivative.expiration_date: On 8/19/2019, the Board of Directors certified vesting of 1,759 performance RSUs. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 745 | $197.57 | $147,189.65 |
DisclosureSEC source: 0000914190-19-000328 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,203 Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:32 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 1,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-19-000328 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 13,290 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000259 · edgar.xml · derivative · entry 16 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,290 Underlying: Common Stock · 13,290 shares Expires 2026-08-07 F10 · derivative.exercise_date: Options to purchase 3,323 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 3,322 shares vest on each of 8/7/2022 and 8/7/2023. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 9,968 | $0.00 Strike: $190.41 | $0.00 |
DisclosureSEC source: 0000914190-19-000259 · edgar.xml · derivative · entry 15 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,968 Underlying: Common Stock · 9,968 shares Expires 2026-08-07 F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 20:11 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,969 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000259 · edgar.xml · derivative · entry 14 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,969 Underlying: Common Stock · 1,969 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,400 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0001562180-19-003162 · primarydocument.xml · derivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,400 Underlying: Common Stock · 5,400 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,400 | $200.00 | $1,080,000.00 |
DisclosureSEC source: 0001562180-19-003162 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189 Read SEC document |
| May 24, 2019 Filed May 29, 2019 20:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003162 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 7,339 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 8 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,339 Underlying: Common Stock · 7,339 shares Expires 2025-08-08 F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 9,786 | $0.00 Strike: $177.32 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,786 Underlying: Common Stock · 9,786 shares Expires 2025-08-08 F5 · derivative.exercise_date: Vests 2,447 shares each on 8/8/2019, 8/8/2020, and 2,446 shares each on 8/8/2021, 8/8/2022 Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,374 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 6 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374 Underlying: Common Stock · 1,374 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F4 · derivative.expiration_date: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerStock Options (Right to buy) · Derivative | 1,505 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,995 Underlying: Common Stock · 1,505 shares Expires 2022-08-07 F3 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 5,995 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerRestricted Stock Units · Derivative | 241 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 241 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 959 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · derivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241 Underlying: Common Stock · 959 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. F2 · derivative.expiration_date: On 8/7/2018, the Board of Directors authorized discretionary vesting for 959 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 438 | $180.14 | $78,901.32 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,189 Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 22:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 959 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003543 · primarydocument.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2017 Filed Oct 30, 2017 20:57 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to buy) · Derivative | 12,670 | $0.00 Strike: $125.05 | $0.00 |
DisclosureSEC source: 0001562180-17-003382 · primarydocument.xml · derivative · entry 4 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,670 Underlying: Common Stock · 12,670 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vest 3,167 shares each on 8/9/2018, 8/9/2019 and 3,168 shares each on 8/9/2020, 8/9/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.